睿知中国医院研究地图
候选清单

苏州苏州大学

苏州大学附属第二医院

Second Affiliated Hospital of Soochow University

在本站收录的 61 种疾病中,这家医院列在其中 17 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

苏州大学附属第二医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma5 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma4 篇牵头论文
  3. 胃癌Stomach cancer32 篇牵头论文
  4. 肺癌Lung cancer64 篇牵头论文牵头 1 项开放试验
  5. 胰腺癌Pancreatic cancer11 篇牵头论文
  6. 乳腺癌Breast cancer27 篇牵头论文牵头 1 项开放试验
  7. 胶质瘤Glioma44 篇牵头论文
  8. 骨肉瘤Osteosarcoma13 篇牵头论文
  9. 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
  10. 尤文肉瘤Ewing sarcoma2 篇牵头论文
  11. 多发性骨髓瘤Multiple myeloma2 篇牵头论文
  12. 淋巴瘤Lymphoma10 篇牵头论文牵头 3 项开放试验
  13. 法布雷病Fabry disease0 篇牵头论文
  14. 杜氏肌营养不良Duchenne muscular dystrophy0 篇牵头论文
  15. 白塞病Behçet disease1 篇牵头论文
  16. IgA 肾病IgA nephropathy1 篇牵头论文
  17. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文

未列出的收录疾病:肝细胞癌、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、神经母细胞瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、冠心病、先天性心脏病、脊柱侧弯、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 2220242025: 112025

苏州有 2 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题放疗技术诱导/同步化疗影像与人工智能
论文中的科室放疗科消化/肝病科耳鼻喉/头颈外科神经外科

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 1120242025: 112025

苏州有 4 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题影像与人工智能分子标志物与基因手术
论文中的科室肿瘤内科放疗科

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 32 篇,占 0.3%。

牵头论文
32
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 4420222023: 101020232024: 8820242025: 552025

苏州有 4 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    分期
    不分期
    开始
    2026-06
    发布
    登记号
    NCT07552402

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南宁、大连、成都、杭州、武汉、石家庄、福州、苏州、银川

  2. 正在招募
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    分期
    III期
    开始
    2025-02
    发布
    登记号
    NCT06731478

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、厦门、合肥、哈尔滨、天津、太原、常州、徐州、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、银川

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题手术腹膜转移与晚期营养与康复
论文中的科室普外/肝胆胰外科肿瘤内科放疗科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文32
  1. Machine learning models for prediction of lymph node metastasis in patients with gastric cancer: a Chinese single-centre study with external validation in an Asian American population.2025BMJ open免费全文
  2. Development and current status of anti-reflux esophagogastrostomy after proximal gastrectomy: a literature review.2025Langenbeck's archives of surgery免费全文
  3. Development and Characterization of the [177Lu]Lu-Labeled Anti-CDH17 Nanobody Derivative for Radioimmunotherapy in the Gastric Cancer Xenograft Model.2025Molecular pharmaceutics免费全文
  4. Postoperative hypotension in gastric cancer patients: causes and clinical approaches.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  5. Metabolic regulation of amino acids provides an important basis for individualized nutritional therapy for patients with gastric cancer during the perioperative period.2025World journal of surgical oncology免费全文
  6. Incidence and risk of remnant gastric cancer after gastrectomy for gastric cancer: a population-based study from the SEER database.2024BMC gastroenterology免费全文
  7. A case-series study of hepatic left lateral segment inversion for surgical field exposure in laparoscopic gastrectomy.2024BMC surgery免费全文
  8. Tumor-derived Prevotella intermedia aggravates gastric cancer by enhancing Perilipin 3 expression.2024Cancer science免费全文
  9. DDX24 promotes tumor progression by mediating hexokinase-1 induced glycolysis in gastric cancer.2024Cellular signalling
  10. MiR-30a-5p isoform -1|1 promotes the progression of gastric cancer by inhibiting TMEM66 and reducing intratumoral cytotoxic T cells.2024Experimental cell research
  11. Investigating MATN3 and ASPN as novel drivers of gastric cancer progression via EMT pathways.2024Human molecular genetics
  12. CircFNTA promotes tumorigenesis and progression of gastric cancer via miR-604/miR-647/SCN8A axis.2024Journal of biochemical and molecular toxicology
  13. The relationship between splenic dose and radiation-induced lymphopenia.2024Journal of radiation research免费全文
  14. RAI2 acts as a tumor suppressor with functional significance in gastric cancer.2023Aging免费全文
  15. High expression of serine protease 2 (PRSS2) associated with invasion, metastasis, and proliferation in gastric cancer.2023Aging免费全文
  16. Decreased KLF3 Expression via miR-660-5p Targeting Suppresses Gastric Cancer Cell Progression.2023Annals of clinical and laboratory science
  17. METTL3 regulates N6-methyladenosine modification of ANGPTL3 mRNA and potentiates malignant progression of stomach adenocarcinoma.2023BMC gastroenterology免费全文
  18. Peripheral CD4+CD25hiCD127low regulatory T cells are increased in patients with gastrointestinal cancer.2023BMC gastroenterology免费全文
  19. Laparoscopic proximal gastrectomy with right-sided overlap and single-flap valvuloplasty (ROSF): a case-series study.2023BMC surgery免费全文
  20. Development and validation of a multiphase CT radiomics nomogram for the preoperative prediction of lymphovascular invasion in patients with gastric cancer.2023Clinical radiology
  21. Exosomal circ_0091741 promotes gastric cancer cell autophagy and chemoresistance via the miR-330-3p/TRIM14/Dvl2/Wnt/β-catenin axis.2023Human cell
  22. MST4 as a novel therapeutic target for autophagy and radiosensitivity in gastric cancer.2023IUBMB life
  23. Targeting ROR1 inhibits glucocorticoid-induced gastric cancer growth.2023Steroids
  24. Inhibition of Musashi-1 enhances chemotherapeutic sensitivity in gastric cancer patient-derived xenografts.2022Experimental biology and medicine (Maywood, N.J.)免费全文
  25. PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report.2022Frontiers in immunology免费全文
  26. Current status of internal hernia after gastrectomy for gastric cancer.2022Langenbeck's archives of surgery
  27. Clinicopathological Analysis and Prognostic Assessment of TCN1 in Patients with Gastric Cancer.2022Surgical innovation
  28. Current status of laparoscopic proximal gastrectomy in proximal gastric cancer: Technical details and oncologic outcomes.2021Asian journal of surgery
  29. TYMSOS drives the proliferation, migration, and invasion of gastric cancer cells by regulating ZNF703 via sponging miR-4739.2021Cell biology international
  30. Mast1 mediates radiation-induced gastric injury via the P38 MAPK pathway.2021Experimental cell research
  31. Esophagus two-step-cut overlap method in esophagojejunostomy after laparoscopic gastrectomy.2021Langenbeck's archives of surgery
  32. UFBP1, a key component in ufmylation, enhances drug sensitivity by promoting proteasomal degradation of oxidative stress-response transcription factor Nrf2.2021Oncogene
中文论文(未计入)4
  1. [Application status of vagus nerve preservation and double-flap technique in laparoscopic proximal gastrectomy].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Artificial intelligence for lymph node metastasis prediction in gastric cancer: research progress].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [A preliminary exploration of reduced port laparoscopic proximal gastrectomy with right-sided overlap and single-flap valvuloplasty (ROSF)].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Immune-Related Pancreatitis Caused by Immune Checkpoint Inhibitor Nivolumab:Report of One Case].2023Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
  1. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer正在招募NCT07552402研究中心不分期2026-06 启动
  2. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer正在招募NCT06731478研究中心III期2025-02 启动
  3. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  4. HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese Patients状态不明NCT05526339研究中心不分期2022-09 启动
  5. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  6. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  7. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  8. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  9. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer已完成NCT03694522研究中心II期2018-09 启动
  10. Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study状态不明NCT03121729研究中心不分期2017-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 64 篇,占 0.3%。

牵头论文
64
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 151520212022: 9920222023: 131320232024: 9920242025: 18182025

苏州有 3 家医院列在肺癌下全国有 251 家医院列在肺癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    The Impact of Thoracic Paravertebral Nerve Block At Different Positions on Pain Relief in Patients Undergoing Single-Port Thoracoscopic Partial Lung Resection
    分期
    不分期
    开始
    2025-01
    发布
    登记号
    NCT06789276

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:苏州大学附属第二医院苏州

  2. 正在招募
    Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
    分期
    I/II期
    开始
    2023-04
    发布
    登记号
    NCT05786924

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、北京、济南、苏州

  3. 即将招募
    YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
    分期
    III期
    开始
    2023-05
    发布
    登记号
    NCT05767892

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、北京、南京、南昌、厦门、台州、合肥、呼和浩特、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、洛阳、济南、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室放疗科影像/核医学科肿瘤内科病理/检验科
牵头的论文64
  1. A combined model integrating radiomics and deep learning based on multiparametric magnetic resonance imaging for classification of brain metastases.2025Acta radiologica (Stockholm, Sweden : 1987)
  2. A Neovascularization and EGFR Dual-Targeting Gold Nanotheranostic System for Non-Small Cell Lung Cancer Treatment.2025Advanced healthcare materials
  3. Distinct CTC Specific RNA Profile Enables NSCLC Early Detection and Dynamic Monitoring of Advanced NSCLC.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  4. Lymphocyte-to-C-reactive protein ratio predicts prognosis in unresectable locally advanced non-small cell lung cancer patients.2025Annals of medicine免费全文
  5. Feasibility and mechanism of 68Ga-FAPI PET/CT in monitoring chemoresistance of non-small cell lung cancer.2025Annals of nuclear medicine
  6. MicroRNA-486: a dual-function biomarker for diagnosis and tumor immune microenvironment characterization in non-small cell lung cancer.2025BMC medical genomics免费全文
  7. The mechanism of E3 ubiquitin ligase HERC1 regulating ferroptosis in lung adenocarcinoma cells.2025Cancer genetics
  8. IGF2BP3 Triggers STAT3 Pathway by Stabilizing SRC RNA in an m6A-Dependent Manner to Promote Lymphatic Metastasis in LUAD.2025Cancer science免费全文
  9. NADH:ubiquinone oxidoreductase core subunit S8 expression and functional significance in non-small cell lung cancer.2025Cell death & disease免费全文
  10. Mitochondrial carrier homolog 2 is important for mitochondrial functionality and non-small cell lung cancer cell growth.2025Cell death & disease免费全文
  11. Expression patterns of MCM8 in lung adenocarcinoma and its correlation with key biological processes.2025European journal of medical research免费全文
  12. Risk factors and intraoperative identification of non-lepidic predominant lung adenocarcinoma presenting as subsolid nodule: A multicenter study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  13. Suppressor of Tumorigenicity 14 inhibits non-small cell lung cancer cell proliferation by suppressing Transketolase O-GlcNAcylation.2025Experimental cell research
  14. Radiomics based on dual-layer spectral detector CT for predicting EGFR mutation status in non-small cell lung cancer.2025Journal of applied clinical medical physics免费全文
  15. Prognostic implications, genomic and immune characteristics of lung adenocarcinoma with lepidic growth pattern.2025Journal of clinical pathology
  16. Targeting the lung tumour stroma: harnessing nanoparticles for effective therapeutic interventions.2025Journal of drug targeting
  17. TRANS: a prediction model for EGFR mutation status in NSCLC based on radiomics and clinical features.2025Respiratory research免费全文
  18. Which descriptor should spread through air spaces (STAS) be incorporated into? T descriptor versus residual tumor classification.2025The journal of pathology. Clinical research免费全文
  19. Comparison of lung lesion assessment using free-breathing dynamic contrast-enhanced 1.5-T MRI with a golden-angle radial stack-of-stars VIBE sequence and CT.2024Acta radiologica (Stockholm, Sweden : 1987)
  20. Keratin 6A (KRT6A) promotes radioresistance, invasion, and metastasis in lung cancer via p53 signaling pathway.2024Aging免费全文
  21. Elevated origin recognition complex subunit 6 expression promotes non-small cell lung cancer cell growth.2024Cell death & disease免费全文
  22. Ectopic Expression of TIGIT in Lung Adenocarcinoma and Its Clinical Significance.2024Critical reviews in eukaryotic gene expression
  23. 2.5D deep learning based on multi-parameter MRI to differentiate primary lung cancer pathological subtypes in patients with brain metastases.2024European journal of radiology
  24. CXCL5 impedes CD8+ T cell immunity by upregulating PD-L1 expression in lung cancer via PXN/AKT signaling phosphorylation and neutrophil chemotaxis.2024Journal of experimental & clinical cancer research : CR免费全文
  25. Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non-small-cell lung cancer.2024Lipids in health and disease免费全文
  26. Tislelizumab combined with GT chemotherapy for intimal sarcoma of inferior vena cava: A case report.2024Medicine免费全文
  27. GIMAP7 inhibits epithelial-mesenchymal transition and glycolysis in lung adenocarcinoma cells via regulating the Smo/AMPK signaling pathway.2024Thoracic cancer免费全文
  28. Identification of epithelial-mesenchymal transition-related biomarkers in lung adenocarcinoma using bioinformatics and lab experiments.2023Aging免费全文
  29. POLRMT over-expression is linked to WNT/beta-catenin signaling, immune infiltration, and unfavorable outcomes in lung adenocarcinoma patients.2023Cancer medicine免费全文
  30. Clinical implications and molecular features of tertiary lymphoid structures in stage I lung adenocarcinoma.2023Cancer medicine免费全文
  31. FDW028, a novel FUT8 inhibitor, impels lysosomal proteolysis of B7-H3 via chaperone-mediated autophagy pathway and exhibits potent efficacy against metastatic colorectal cancer.2023Cell death & disease免费全文
  32. Clinical profiles and intraoperative identification of complex glands in stage I lung adenocarcinoma.2023European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  33. CYFIP2 serves as a prognostic biomarker and correlates with tumor immune microenvironment in human cancers.2023European journal of medical research免费全文
  34. EUS-guided ethanol ablation for management of lung carcinoma (with video).2023Gastrointestinal endoscopy
  35. Identification of WD-Repeat Protein 72 as a Novel Prognostic Biomarker in Non-Small-Cell Lung Cancer.2023Mediators of inflammation免费全文
  36. Sarcopenia as a Determinant of the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Meta-Analysis.2023Nutrition and cancer
  37. Plasma metabolomics for the assessment of the progression of non-small cell lung cancer.2023The International journal of biological markers
  38. Characteristics and risk factors for advanced lung cancer with pulmonary embolism: A cross-sectional, case-control study.2023The clinical respiratory journal免费全文
  39. Characterization of TCF-1 and its relationship between CD8+ TIL densities and immune checkpoints and their joint influences on prognoses of lung adenocarcinoma patients.2023Thoracic cancer免费全文
  40. Oncogenic zinc finger protein ZNF687 accelerates lung adenocarcinoma cell proliferation and tumor progression by activating the PI3K/AKT signaling pathway.2023Thoracic cancer免费全文
  41. Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib.2022BMC cancer免费全文
  42. Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study.2022BMC pulmonary medicine免费全文
  43. Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 and Its Related Molecules as Potential Biomarkers in Small-Cell Lung Cancer.2022BioMed research international免费全文
  44. Roles of DNA polymerase ζ in the radiotherapy sensitivity and oxidative stress of lung cancer cells.2022Cancer chemotherapy and pharmacology
  45. Comment on "clinicopathological features, survival outcomes, and appropriate surgical approaches for stage I acinar and papillary predominant lung adenocarcinoma".2022Cancer medicine免费全文
  46. Targeting sphingosine kinase 1/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth.2022Cell death & disease免费全文
  47. Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients.2022Clinical imaging
  48. Identification of the mitochondrial protein ADCK2 as a therapeutic oncotarget of NSCLC.2022International journal of biological sciences免费全文
  49. Log odds of positive lymph nodes is a robust predictor of survival and benefits from postoperative radiotherapy in stage IIIA-N2 resected non-small cell lung cancer.2022Thoracic cancer免费全文
  50. Potentiated lung adenocarcinoma (LUAD) cell growth, migration and invasion by lncRNA DARS-AS1 via miR-188-5p/ KLF12 axis.2021Aging免费全文
  51. LncRNA LOC100129620 promotes osteosarcoma progression through regulating CDK6 expression, tumor angiogenesis, and macrophage polarization.2021Aging免费全文
  52. Overexpression of hsa_circ_0002874 promotes resistance of non-small cell lung cancer to paclitaxel by modulating miR-1273f/MDM2/p53 pathway.2021Aging免费全文
  53. Characterization of Extracapsular Lymph Node Involvement and Its Clinicopathological Characteristics in Stage II-IIIA Lung Adenocarcinoma.2021Annals of surgical oncology
  54. ASO Author Reflections: Old Song, New Sung-Extracapsular Extension in Lung Cancer in the Era of Eighth-Edition N Classification.2021Annals of surgical oncology
  55. Stromal-derived miR-486-5p promotes metastasis of non-small-cell lung cancer cells by targeting the CADM1/tight junctions axis in vascular endothelial cells.2021Cell biology international
  56. The requirement of mitochondrial RNA polymerase for non-small cell lung cancer cell growth.2021Cell death & disease免费全文
  57. M2 macrophage-derived exosomal long non-coding RNA AGAP2-AS1 enhances radiotherapy immunity in lung cancer by reducing microRNA-296 and elevating NOTCH2.2021Cell death & disease免费全文
  58. Clinical implications of the pattern of recurrence of pN2 non-small-cell lung cancer.2021European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  59. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.2021European journal of pharmacology
  60. FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer.2021Frontiers in immunology免费全文
  61. Differentiation of pulmonary sclerosing pneumocytoma from solid malignant pulmonary nodules by radiomic analysis on multiphasic CT.2021Journal of applied clinical medical physics免费全文
  62. Letter to the Editor: Clinical Implications of Postoperative Radiotherapy on Patient Survival in Stage IIIA Resected Lung Cancer: More Variables Should Be Considered.2021Journal of the National Comprehensive Cancer Network : JNCCN
  63. Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.2021Lung cancer (Amsterdam, Netherlands)
  64. A novel GHR-ALK fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case report.2021The Journal of international medical research免费全文
中文论文(未计入)5
  1. [Radiotherapy Combined with Immunotherapy and Chemotherapy Improves Prognosis and Demonstrates Synergistic Effects in Extensive-stage Small Cell Lung Cancer].2024Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  2. [Efficacy Analysis of High-flow Nasal Oxygen Therapy in Patients 
Accepting Single-port Video-assisted Thoracoscopic Lobectomy].2022Zhongguo fei ai za zhi = Chinese journal of lung cancerRCT免费全文
  3. [Progress in Single-cell RNA Sequencing of Lung Adenocarcinoma].2021Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  4. [Clinicopathological and genetic features of metastatic lung cancer to the adrenal glands: report of four cases].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
  5. [Differential diagnosis of pure ground glass nodules in lung with spectral CT imaging].2021Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
  1. The Impact of Thoracic Paravertebral Nerve Block At Different Positions on Pain Relief in Patients Undergoing Single-Port Thoracoscopic Partial Lung Resection即将招募NCT06789276牵头方不分期2025-01 启动
  2. A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer状态不明NCT06047860牵头方II期2023-06 启动
  3. Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)状态不明NCT05603013牵头方II期2022-10 启动
  4. Preoperative and Postoperative ctDNA Comparison in Early Stage Lung Cancer状态不明NCT03805256牵头方2018-05 启动
  5. YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations即将招募NCT05767892研究中心III期2023-05 启动
  6. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies正在招募NCT05786924研究中心I/II期2023-04 启动
  7. ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors进行中,不再招募NCT05671510研究中心III期2023-06 启动
  8. Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)已完成NCT05298423研究中心III期2022-05 启动
  9. Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer已终止NCT04921358研究中心III期2021-07 启动
  10. A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer已终止NCT04746924研究中心III期2021-05 启动
  11. A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC状态不明NCT04416035研究中心III期2020-08 启动
  12. Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer已终止NCT04422392研究中心II期2020-07 启动
  13. Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)已完成NCT03358875研究中心III期2017-11 启动
  14. Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer已完成NCT03117335研究中心III期2011-11 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胰腺癌

Pancreatic cancer

2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.2%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 0020222023: 2220232024: 3320242025: 332025

苏州有 2 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases
    分期
    I期
    开始
    2024-01
    发布
    登记号
    NCT06278454

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、天津、苏州、郑州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室普外/肝胆胰外科消化/肝病科
牵头的论文11
  1. GALNT4-induced O-GalNAc glycosylation of MUC1 accelerates the invasive phenotype of PDAC.2025Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  2. A Phase I/II Study Protocol of a Novel Neoadjuvant 'PRaG' Regimen (Radiotherapy, GM-CSF, and Cadonilimab) with AG Chemotherapy to Improve Resectability in Locally Advanced Pancreatic Ductal Adenocarcinoma: The NeoPRAG Study.2025Technology in cancer research & treatment免费全文
  3. The impact of the muscle mass-to-fat ratio on the prognosis of patients undergoing pancreaticoduodenectomy for pancreatic cancer.2025The Kaohsiung journal of medical sciences免费全文
  4. Macroscopic on-site magnifier-based evaluation to estimate visible tissue core cut-off lengths using EUS-FNA with 22-gauge needles.2024Chinese medical journal免费全文
  5. YAP-LAMB3 axis dictates cellular resistance of pancreatic ductal adenocarcinoma cells to gemcitabine.2024Molecular carcinogenesis
  6. PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report.2024World journal of gastroenterology免费全文
  7. Identification of matrix-remodeling associated 5 as a possible molecular oncotarget of pancreatic cancer.2023Cell death & disease免费全文
  8. EUS-guided ethanol ablation for management of lung carcinoma (with video).2023Gastrointestinal endoscopy
  9. Individualized prognostic signature for pancreatic carcinoma validated by integrating immune-related gene pairs (IRGPs).2021Bioengineered免费全文
  10. Elevated expression of nuclear receptor-binding SET domain 3 promotes pancreatic cancer cell growth.2021Cell death & disease免费全文
  11. Hepatobiliary and Pancreatic: Endoscopic resection of biliary ductal tumour.2021Journal of gastroenterology and hepatology
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases正在招募NCT06278454研究中心I期2024-01 启动
  2. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  3. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

乳腺癌

Breast cancer

2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 27 篇,占 0.2%。

牵头论文
27
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 6620222023: 1120232024: 7720242025: 772025

苏州有 2 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC
    分期
    不分期
    开始
    2024-02
    发布
    登记号
    NCT06235931

    年龄 65 岁 至 未注明;仅女性(登记的条件)

    牵头:苏州大学附属第二医院苏州

  2. 正在招募
    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
    分期
    III期
    开始
    2023-12
    发布
    登记号
    NCT06079983

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 60 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、大连、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、梅州、武汉、汕头、沈阳、洛阳、济南、湛江、石家庄、福州、苏州、衡阳、襄阳、西宁、西安、贵阳、遵义、郑州、重庆、长春、长沙、青岛

  3. 正在招募
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    分期
    II期
    开始
    2023-12
    发布
    登记号
    NCT06107686

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南宁、南昌、台州、合肥、哈尔滨、太原、广州、徐州、成都、杭州、桂林、梅州、武汉、汕头、沈阳、济南、潍坊、苏州、襄阳、西安、郑州、重庆、长春、长沙、青岛

  4. 邀请入组
    A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
    分期
    II期
    开始
    2025-08
    发布
    登记号
    NCT07376629

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 22 家列出的医院为研究中心上海、临沂、南京、厦门、合肥、哈尔滨、天津、太原、安阳、广州、徐州、成都、杭州、武汉、沈阳、济南、福州、苏州、西安、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室普外/肝胆胰外科肿瘤内科病理/检验科放疗科

这些论文过半是实验室或动物研究。

牵头的论文27
  1. Radiological-pathological correlation in encapsulated papillary carcinoma of the breast.2026Annals of diagnostic pathology
  2. Circ_0057582 inhibits breast cancer progression via hnRNPF/YAP/SOX9 axis and M2 polarization in TAMs by autophagic degradation of ISG15.2026Biochemical pharmacology
  3. Collagen Hydrogel Loaded With 9-cisRA-Lip Is an Option for Treatment of Secondary Lymphedema after Surgery.2025Cancer biotherapy & radiopharmaceuticals
  4. Hyaluronic acid and polyvinyl alcohol-based radioresponsive hydrogel for combined radioimmunotherapy of breast cancer bone metastasis.2025Carbohydrate polymers
  5. Study on Heparanase Promoting Breast Cancer Cell Proliferation and Inhibiting NK Cell Cytolytic Activity Via the PD-1/PD-L1 Pathway.2025Clinical breast cancer
  6. Development and validation of a novel sodium-overload related genes signature for prognostic prediction in breast cancer: integrating bioinformatics and experimental approaches.2025Frontiers in immunology免费全文
  7. Igniting tumour microenvironment in triple-negative breast cancer using a mannose/hyaluronic acid dual-coated Ganoderma polysaccharide-superparamagnetic iron oxide nanocomplex for combinational therapies.2025Journal of drug targeting
  8. Innovative applications of visualized thermosensitive color-changing personalized boluses in post-mastectomy radiotherapy: a dosimetric analysis.2025Radiation oncology (London, England)RCT免费全文
  9. Leucine rich repeat containing 15 promotes triple-negative breast cancer proliferation and invasion via the ITGB1/FAK/PI3K signalling pathway.2025Scientific reports免费全文
  10. A novel SERS-lateral flow assay (LFA) tray for monitoring of miR-155-5p during pyroptosis in breast cancer cells.2024Analytical methods : advancing methods and applications
  11. The novel circRNA circ_0045881 inhibits cell proliferation and invasion by targeting mir-214-3p in triple-negative breast cancer.2024BMC cancer免费全文
  12. A comprehensive evaluation of circ_0065214/ miR-188-3p/GPNMB axis in breast cancer.2024Cellular signalling
  13. Exosomal miR-122-3p represses the growth and metastasis of MCF-7/ADR cells by targeting GRK4-mediated activation of the Wnt/β-catenin pathway.2024Cellular signalling
  14. SNHG14 promotes triple-negative breast cancer cell proliferation, invasion, and chemoresistance by regulating the ERK/MAPK signaling pathway.2024IUBMB life
  15. Metabolism-regulating non-coding RNAs in breast cancer: roles, mechanisms and clinical applications.2024Journal of biomedical science免费全文
  16. LINC01929 Is a Prognostic Biomarker for Multiple Tumours and Promotes Cell Proliferation in Breast Cancer Through the TNF/STAT3 Axis.2024Journal of cellular and molecular medicine免费全文
  17. Letter to the editor regarding "Association between gout and subsequent breast cancer: a retrospective cohort study including 67,598 primary care patients in Germany".2023Breast cancer research and treatment
  18. Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression.2022Breast cancer research and treatment
  19. HOXD9 transcriptionally induced UXT facilitate breast cancer progression via epigenetic modification of RND3.2022Cellular signalling
  20. KLF14 alleviated breast cancer invasion and M2 macrophages polarization through modulating SOCS3/RhoA/Rock/STAT3 signaling.2022Cellular signalling
  21. LINC00680 modulates docetaxel resistance in breast cancer via the miR-320b/CDKL5 axis.2022International journal of immunopathology and pharmacology免费全文
  22. A novel prognostic model associated with the overall survival in patients with breast cancer based on lipid metabolism-related long noncoding RNAs.2022Journal of clinical laboratory analysis免费全文
  23. CTCF-Induced lncRNA C5orf66-AS1 Facilitates the Progression of Triple-Negative Breast Cancer via Sponging miR-149-5p to Up-Regulate CTCF and CTNNB1 to Activate Wnt/β-Catenin Pathway.2022Molecular and cellular biology免费全文
  24. Transcription factor KLF2 enhances the sensitivity of breast cancer cells to cisplatin by suppressing kinase WEE1.2021Cancer biology & therapy免费全文
  25. Lobetyolin inhibits the proliferation of breast cancer cells via ASCT2 down-regulation-induced apoptosis.2021Human & experimental toxicology
  26. The role of ferroptosis-related genes for overall survival prediction in breast cancer.2021Journal of clinical laboratory analysis免费全文
  27. B7-H3 on breast cancer cell MCF7 inhibits IFN-γ release from tumour-infiltrating T cells.2021Pathology, research and practice
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
  1. A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC正在招募NCT06235931牵头方不分期2024-02 启动
  2. Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)状态不明NCT05603013牵头方II期2022-10 启动
  3. A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC邀请入组NCT07376629研究中心II期2025-08 启动
  4. A Study of YL202 in Selected Patients With Advanced Solid Tumors正在招募NCT06107686研究中心II期2023-12 启动
  5. JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects正在招募NCT06079983研究中心III期2023-12 启动
  6. PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC进行中,不再招募NCT06419621研究中心III期2024-06 启动
  7. A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer状态不明NCT05433480研究中心III期2022-05 启动
  8. Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer状态不明NCT01642771研究中心III期2012-06 启动
  9. Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer已终止NCT00912444研究中心III期2009-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胶质瘤

Glioma

2021–2025 年中国大陆作者发表的 7,081 篇胶质瘤 PubMed 英文论文中,这家医院牵头了 44 篇,占 0.6%。

牵头论文
44
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 6620222023: 121220232024: 4420242025: 11112025

苏州有 4 家医院列在胶质瘤下全国有 187 家医院列在胶质瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study of GC101 TIL in Brain Glioma (Soochow2)
    分期
    早期I期
    开始
    2021-05
    发布
    登记号
    NCT04943913

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经外科放疗科神经内科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文44
  1. Selenoprotein P drives glioma malignancy via LRP8-dependent activation of Wnt/β-catenin signaling.2026Cellular signalling
  2. Procollagen C-protease enhancer protein promotes glioma growth by activating ERK signaling.2025Asia-Pacific journal of clinical oncology免费全文
  3. MDA-9/Syntenin promotes glioma cell proliferation and invasion via exosome-mediated activation of the PI3K-AKT signaling pathway.2025Biochemical and biophysical research communications
  4. FDX1 facilitates elesclomol-induced cuproptosis and promotes glioblastoma development via transcription factor NFKB1.2025Biochemical pharmacology
  5. KIF4A Promotes Glioblastoma Malignant Progression and Transmission of Temozolomide Resistance in the Tumor Microenvironment via the HIF1A/VEGFA Axis.2025CNS neuroscience & therapeutics免费全文
  6. Amlodipine synergizes with temozolomide against glioma stem cells by modulating MGMT expression through downregulation of the AKT/GSK3β/β-catenin axis.2025Cellular signalling
  7. SRBD1 Regulates the Cell Cycle, Apoptosis, and M2 Macrophage Polarization via the RPL11-MDM2-p53 Pathway in Glioma.2025Environmental toxicology
  8. The miR-192/EGR1-HOXB9 loop inhibits immune evasion in glioma by arresting their NSC phenotypes.2025International immunopharmacology
  9. The miR-192-EGR1/HOXB9 Loop Regulates Glioma Cell Stemness and Malignant Phenotypes by Promoting Their Mesenchymal Transition.2025Journal of cellular and molecular medicine免费全文
  10. KIF4A Inhibits Ferroptosis in Glioblastoma via the CHMP4B/GPX4 Axis and Promotes Temozolomide Resistance.2025Molecular carcinogenesis
  11. KRT80, Regulated by RNF8-Mediated Ubiquitination, Contributes to Glucose Metabolic Reprogramming and Progression of Glioblastoma.2025Neurochemical research
  12. Immuno-oncological interactions between meningeal lymphatics and glioblastoma: from mechanisms to therapies.2025Theranostics免费全文
  13. Transformed astrocytes confer temozolomide resistance on glioblastoma via delivering ALKBH7 to enhance APNG expression after educating by glioblastoma stem cells-derived exosomes.2024CNS neuroscience & therapeutics免费全文
  14. Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial.2024Cancer biology & medicine免费全文
  15. Glioma stem cell-derived exosomes induce the transformation of astrocytes via the miR-3065-5p/DLG2 signaling axis.2024Glia
  16. SENP1-Mediated deSUMOylation Regulates the Tumor Remodeling of Glioma Stem Cells Under Hypoxic Stress.2024Technology in cancer research & treatment免费全文
  17. Interferon-γ inducible protein 30 promotes the epithelial-mesenchymal transition-like phenotype and chemoresistance by activating EGFR/AKT/GSK3β/β-catenin pathway in glioma.2023CNS neuroscience & therapeutics免费全文
  18. Exosomal miR-6733-5p mediates cross-talk between glioblastoma stem cells and macrophages and promotes glioblastoma multiform progression synergistically.2023CNS neuroscience & therapeutics免费全文
  19. Upregulation of the ZNF148/PTX3 axis promotes malignant transformation of dendritic cells in glioma stem-like cells microenvironment.2023CNS neuroscience & therapeutics免费全文
  20. RNA-binding protein DHX9 promotes glioma growth and tumor-associated macrophages infiltration via TCF12.2023CNS neuroscience & therapeutics免费全文
  21. Exosome-Mediated Transfer of circ-GLIS3 Enhances Temozolomide Resistance in Glioma Cells Through the miR-548m/MED31 Axis.2023Cancer biotherapy & radiopharmaceuticals
  22. LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells.2023Cancer immunology, immunotherapy : CII免费全文
  23. LncRNA SPRY4-IT1 facilitates cell proliferation and angiogenesis of glioma via the miR-101-3p/EZH2/VEGFA signaling axis.2023Cancer medicine免费全文
  24. The FDX1 methylation regulatory mechanism in the malignant phenotype of glioma.2023Genomics
  25. PA2G4P4 Promotes Glioma Cell Migration and Tumorigenesis through the PTEN/AKT/mTOR Signaling Pathway.2023Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  26. HDAC1 mediates epithelial-mesenchymal transition and promotes cancer cell invasion in glioblastoma.2023Pathology, research and practice
  27. YME1L overexpression exerts pro-tumorigenic activity in glioma by promoting Gαi1 expression and Akt activation.2023Protein & cell免费全文
  28. Rare adult pilocytic astrocytoma of the septum pellucidum with novel RIN2::BRAF fusion.2023Virchows Archiv : an international journal of pathology
  29. Molecular characteristics of single patient-derived glioma stem-like cells from primary and recurrent glioblastoma.2022Anti-cancer drugs免费全文
  30. MEOX2-mediated regulation of Cathepsin S promotes cell proliferation and motility in glioma.2022Cell death & disease免费全文
  31. RIT1 Promotes Glioma Proliferation and Invasion via the AKT/ERK/NF-ĸB Signaling Pathway.2022Journal of molecular neuroscience : MN
  32. TM4SF1 promotes glioma malignancy through multiple mechanisms.2022Neoplasma
  33. GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair.2022Oncogene
  34. Gliosarcoma with osteosarcomatous component: A case report and short review illustration.2022Pathology, research and practice
  35. Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells.2021Aging免费全文
  36. A retrospective analysis of the risk factors affecting recurrence time in patients with recurrent glioblastoma.2021Annals of palliative medicine
  37. Integrative analysis of TP73 profile prognostic significance in WHO grade II/III glioma.2021Cancer medicine免费全文
  38. Circ_0001367 inhibits glioma proliferation, migration and invasion by sponging miR-431 and thus regulating NRXN3.2021Cell death & disease免费全文
  39. GBP5 drives malignancy of glioblastoma via the Src/ERK1/2/MMP3 pathway.2021Cell death & disease免费全文
  40. Do the combination of multiparametric MRI-based radiomics and selected blood inflammatory markers predict the grade and proliferation in glioma patients?2021Diagnostic and interventional radiology (Ankara, Turkey)免费全文
  41. FHL1 promotes glioblastoma aggressiveness through regulating EGFR expression.2021FEBS letters
  42. Doxorubicin Delivered via ApoE-Directed Reduction-Sensitive Polymersomes Potently Inhibit Orthotopic Human Glioblastoma Xenografts in Nude Mice.2021International journal of nanomedicine免费全文
  43. Self‑renewal signaling pathways and differentiation therapies of glioblastoma stem cells (Review).2021International journal of oncology
  44. Bioinformatics analysis reveals a stem cell-expressed circ-Serpine2-mediated miRNA-mRNA regulatory subnetwork in the malignant progression of glioma.2021Journal of translational medicine免费全文
中文论文(未计入)1
  1. [Characteristics and regulatory mechanisms of lipid metabolism remodeling after malignant transformation of glioma-associated macrophages].2022Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma状态不明NCT05752877牵头方不分期2021-05 启动
  2. Study of GC101 TIL in Brain Glioma (Soochow2)正在招募NCT04943913研究中心早期I期2021-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 13 篇,占 0.6%。

牵头论文
13
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 3320222023: 1120232024: 3320242025: 112025

苏州有 14 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室神经外科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文13
  1. STUB1-mediated ubiquitination of SLC25A10 regulates mitochondrial function and drives osteosarcoma progression: A novel therapeutic target.2025Cellular signalling
  2. KAT7 serves as an oncogenic gene and regulates CCL3 expression via STAT1 signaling in osteosarcoma.2024Biochemical and biophysical research communications
  3. Relationship between surgical compliance and survival outcome in patients with Ewing sarcoma.2024Indian journal of cancer
  4. Mitochondria targeted biomimetic platform for chemo/photodynamic combination therapy against osteosarcoma.2024International journal of pharmaceutics
  5. A Feedback Loop of LINC00665 and the Wnt Signaling Pathway Expedites Osteosarcoma Cell Proliferation, Invasion, and Epithelial-Mesenchymal Transition.2023Orthopaedic surgery免费全文
  6. ADCK1 is a potential therapeutic target of osteosarcoma.2022Cell death & disease免费全文
  7. Identification of Gαi3 as a promising target for osteosarcoma treatment.2022International journal of biological sciences免费全文
  8. Gliosarcoma with osteosarcomatous component: A case report and short review illustration.2022Pathology, research and practice
  9. LncRNA LOC100129620 promotes osteosarcoma progression through regulating CDK6 expression, tumor angiogenesis, and macrophage polarization.2021Aging免费全文
  10. COL3A1 and Its Related Molecules as Potential Biomarkers in the Development of Human Ewing's Sarcoma.2021BioMed research international免费全文
  11. ARHGEF3 Associated with Invasion, Metastasis, and Proliferation in Human Osteosarcoma.2021BioMed research international免费全文
  12. miRNA-296-5p functions as a potential tumor suppressor in human osteosarcoma by targeting SND1.2021Chinese medical journal免费全文
  13. Propofol suppresses osteosarcoma cell function by regulating FOXO1/TUSC7.2021The Journal of pharmacy and pharmacology
早期论文(2016–2020 年)9
  1. MicroRNA-187 suppresses the proliferation migration and invasion of human osteosarcoma cells by targeting MAPK7.2020Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  2. High Expression of N-Acetylgalactosaminyl-transferase 1 (GALNT1) Associated with Invasion, Metastasis, and Proliferation in Osteosarcoma.2020Medical science monitor : international medical journal of experimental and clinical research
  3. Proliferation inhibition and apoptosis promotion by dual silencing of VEGF and Survivin in human osteosarcoma.2019Acta biochimica et biophysica Sinica
  4. EP1 receptor is involved in prostaglandin E2-induced osteosarcoma growth.2019Bosnian journal of basic medical sciences
  5. TCF3-activated LINC00152 exerts oncogenic role in osteosarcoma through regulating miR-1182/CDK14 axis.2019Pathology, research and practice
  6. Long noncoding RNA SNHG6 promotes osteosarcoma cell proliferation through regulating p21 and KLF2.2018Archives of biochemistry and biophysics
  7. MiR-299-5p targets cell cycle to promote cell proliferation and progression of osteosarcoma.2018European review for medical and pharmacological sciences
  8. The anti-tumor effect of pachymic acid on osteosarcoma cells by inducing PTEN and Caspase 3/7-dependent apoptosis.2018Journal of natural medicines
  9. miR-29 Family Inhibits Resistance to Methotrexate and Promotes Cell Apoptosis by Targeting COL3A1 and MCL1 in Osteosarcoma.2018Medical science monitor : international medical journal of experimental and clinical research

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

苏州有 7 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

苏州有 3 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.1%。

牵头论文
2
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

苏州有 2 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    发布
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  2. 正在招募
    A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
    分期
    I期
    开始
    2025-12
    发布
    登记号
    NCT07179679

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、南京、南充、南昌、广州、承德、苏州、西安、重庆

  3. 正在招募
    UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
    分期
    不分期
    开始
    2024-04
    发布
    登记号
    NCT06279026

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题联合用药
牵头的论文2
  1. Multiple myeloma with high expression of SLC7A11 is sensitive to erastin-induced ferroptosis.2024Apoptosis : an international journal on programmed cell death
  2. Anti-BCMA-engineered exosomes for bortezomib-targeted delivery in multiple myeloma.2024Blood advances免费全文
中文论文(未计入)5
  1. [The Role and Possible Mechanism of T Cell Costimulatory Molecule CD28 Activation in Pathogenesis of Multiple Myeloma].2025Zhongguo shi yan xue ye xue za zhi
  2. [The Impact of SRSF1 -Mediated Alternative Splicing of RBBP6 on the Proliferation of Multiple Myeloma Cells].2024Zhongguo shi yan xue ye xue za zhi
  3. [Bone Marrow Adipocytes Promote the Survival of Multiple Myeloma Cells and Up-Regulate Their Chemoresistance].2023Zhongguo shi yan xue ye xue za zhi
  4. [Clinical Significance of CD28 Expression in Newly Diagnosed Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
  5. [Effect of the Connexin 43 Coupling to the Biobehavior of Multiple Myeloma Cells].2021Zhongguo shi yan xue ye xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma状态不明NCT05857982牵头方I/II期2023-05 启动
  2. Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma状态不明NCT02027220牵头方II期2013-12 启动
  3. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  4. A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors正在招募NCT07179679研究中心I期2025-12 启动
  5. UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma正在招募NCT06279026研究中心不分期2024-04 启动
  6. A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects状态不明NCT05646758研究中心I期2023-03 启动
  7. Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma状态不明NCT04186052研究中心早期I期2019-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

淋巴瘤

Lymphoma

2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.3%。

牵头论文
10
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 0020232024: 1120242025: 552025

苏州有 2 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下

这家医院参与的开放试验 6

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.
    分期
    早期I期
    开始
    2026-06
    发布
    登记号
    NCT07598578

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:苏州大学附属第二医院苏州

  2. 正在招募
    Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study
    分期
    II期
    开始
    2025-06
    发布
    登记号
    NCT07002099

    年龄 18 岁 至 未注明(登记的条件)

    牵头:苏州大学附属第二医院苏州

  3. 即将招募
    Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
    分期
    不分期
    开始
    2024-02
    发布
    登记号
    NCT06289959

    年龄 18 岁 至 未注明(登记的条件)

    牵头:苏州大学附属第二医院苏州

  4. 正在招募
    A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
    分期
    I/II期
    开始
    2025-07
    发布
    登记号
    NCT07124936

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心北京、南宁、南昌、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、长春、长沙

  5. 正在招募
    Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    分期
    III期
    开始
    2024-05
    发布
    登记号
    NCT06521255

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、乌鲁木齐、北京、南昌、天津、广州、成都、杭州、武汉、济南、温州、苏州、郑州、重庆、长春、长沙

  6. 正在招募
    A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
    分期
    I期
    开始
    2024-08
    发布
    登记号
    NCT06615193

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心南昌、天津、徐州、杭州、济南、苏州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文10
  1. Circulating tumor DNA from blood and cerebrospinal fluid in DLBCL: simultaneous evaluation of mutations, IG rearrangement, and IG clonality.2025British journal of cancer免费全文
  2. Glofitamab treatment of Richter transformation with isolated central nervous system involvement: a case report.2025Frontiers in immunology免费全文
  3. An anti-CD19-exosome delivery system navigates the blood-brain barrier for targeting of central nervous system lymphoma.2025Journal of nanobiotechnology免费全文
  4. Combined Inhibition of XPO1 and DNA Methylation Exerts Synergistic Effects in DLBCL.2025Molecular carcinogenesis
  5. A novel cancer-associated fibroblast-related gene signature for predicting diffuse large B cell lymphoma prognosis using weighted gene co-expression network analysis and machine learning.2025The Journal of international medical research免费全文
  6. A promising natural product in diffuse large B-cell lymphoma therapy by targeting PIM1.2024Annals of hematology
  7. Diffuse large B-cell lymphoma-derived exosomes push macrophage polarization toward M2 phenotype via GP130/STAT3 signaling pathway.2022Chemico-biological interactions
  8. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma via M2 macrophage interactions: A bioinformatic analysis of the tumor microenvironment.2022Frontiers in immunology免费全文
  9. EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16.2022Leukemia & lymphoma
  10. piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL.2021Blood
它在 ClinicalTrials.gov 上的全部试验(任何状态)16
  1. An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.正在招募NCT07598578牵头方早期I期2026-06 启动
  2. Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study正在招募NCT07002099牵头方II期2025-06 启动
  3. Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL即将招募NCT06289959牵头方不分期2024-02 启动
  4. Chidamide in Patients With Recurrent and Refractory Diffuse Large b状态不明NCT05690191牵头方2021-06 启动
  5. A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma正在招募NCT07124936研究中心I/II期2025-07 启动
  6. A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor正在招募NCT06615193研究中心I期2024-08 启动
  7. Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma正在招募NCT06521255研究中心III期2024-05 启动
  8. Obinutuzumab in Chinese Real-world Patients With iNHL状态不明NCT05968001研究中心2023-07 启动
  9. A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .状态不明NCT05959694研究中心I/II期2023-10 启动
  10. TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)已终止NCT06106841研究中心I/II期2023-10 启动
  11. Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma已完成NCT04849351研究中心II期2021-04 启动
  12. A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.进行中,不再招募NCT05395533研究中心I期2020-09 启动
  13. The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies状态不明NCT04184414研究中心早期I期2018-01 启动
  14. A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection已完成NCT04569838研究中心II期2012-05 启动
  15. A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)已终止NCT01287741研究中心III期2011-07 启动
  16. A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma已终止NCT00486759研究中心III期2007-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年没有牵头法布雷病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

苏州有 3 家医院列在法布雷病下全国有 80 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年没有牵头杜氏肌营养不良的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

苏州有 3 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

苏州有 3 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科
牵头的论文1
  1. Identification of biomarkers for abdominal aortic aneurysm in Behçet's disease via mendelian randomization and integrated bioinformatics analyses.2024Journal of cellular and molecular medicine免费全文
早期论文(2016–2020 年)1
  1. [Progress in interferon: A treatment of Behcet syndrome].2020Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

苏州有 6 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

苏州有 4 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury已完成NCT06888115研究中心I期2025-03 启动

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

苏州大学附属第二医院

Second Affiliated Hospital of Soochow University

苏州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Second Affiliated Hospital of SooChow University; General Hospital of Nuclear Industry; Sino-France Friendship Hospital

提出更正下载数据